Bradley K Ackerson
Overview
Explore the profile of Bradley K Ackerson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rayens E, Sy L, Qian L, Wu J, Ackerson B, Luo Y, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39979209
Objectives: In an interim analysis, we evaluated vaccine effectiveness (VE) against herpes zoster (HZ) and postherpetic neuralgia (PHN) and safety of recombinant zoster vaccine (RZV) in adults aged ≥50 years...
2.
Rayens E, Ku J, Sy L, Qian L, Ackerson B, Luo Y, et al.
Influenza Other Respir Viruses
. 2024 Dec;
18(12):e70025.
PMID: 39696975
This retrospective cohort study evaluated the comparative vaccine effectiveness (cVE) of licensed standard-dose cell-based versus egg-based influenza vaccines in preventing influenza hospitalization among adults 18-64 years during the 2022-2023 season....
3.
Tartof S, Frankland T, Puzniak L, Slezak J, Ackerson B, Hong V, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2449944.
PMID: 39666343
No abstract available.
4.
Lewnard J, Mahale P, Malden D, Hong V, Ackerson B, Lewin B, et al.
Nat Commun
. 2024 Oct;
15(1):8550.
PMID: 39362845
The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023-24. However, this surge in infections was not accompanied by COVID-19 hospitalizations...
5.
Bruxvoort K, Sy L, Slezak J, Ackerson B, Qian L, Qiu S, et al.
Hum Vaccin Immunother
. 2024 Sep;
20(1):2397872.
PMID: 39222955
HepB-CpG is a licensed adjuvanted two-dose hepatitis B vaccine for adults, with limited data on exposure during pregnancy. We assessed the risk of pregnancy outcomes among individuals who received HepB-CpG...
6.
Ku J, Rayens E, Sy L, Qian L, Ackerson B, Luo Y, et al.
Clin Infect Dis
. 2024 Aug;
79(5):1283-1292.
PMID: 39166857
Background: Influenza causes substantial morbidity, particularly among older individuals. Updated data on the effectiveness of currently licensed vaccines in this population are needed. Methods: At Kaiser Permanente Southern California, we...
7.
Lewnard J, Hong V, Grant L, Ackerson B, Bruxvoort K, Pomichowski M, et al.
J Infect Dis
. 2024 Aug;
230(5):e1082-e1091.
PMID: 39101606
Background: Pneumococcal carriage is associated with increased acquisition and duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults. While pneumococcal conjugate vaccines (PCVs) prevent carriage of vaccine-serotype...
8.
Tartof S, Slezak J, Puzniak L, Frankland T, Ackerson B, Jodar L, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae370.
PMID: 39015348
We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2...
9.
Ackerson B, Tartof S, Chen L, Contreras R, Reyes I, Ku J, et al.
J Infect Dis
. 2024 Jun;
230(5):e1101-e1111.
PMID: 38941351
Background: Urinary tract infections (UTIs) occur commonly and often recur. However, recent data on the epidemiology of recurrent UTI (rUTI) are scarce. Methods: Between 1 January 2016 and 31 December...
10.
Tartof S, Slezak J, Frankland T, Puzniak L, Hong V, Ackerson B, et al.
JAMA Intern Med
. 2024 Jun;
184(8):932-940.
PMID: 38913355
Importance: Data describing the early additional protection afforded by the recently recommended BNT162b2 XBB vaccine (Pfizer-BioNTech; 2023-2024 formulation) are limited. Objective: To estimate the association between receipt of the BNT162b2...